Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma (original) (raw)
Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
Rita Rizzi
Pharmaceuticals, 2021
View PDFchevron_right
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma
Alessandro Allegra
European Journal of Haematology, 2013
View PDFchevron_right
Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Shmuel Yaccoby
Immunotherapy, 2016
View PDFchevron_right
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development
Nimra Iftikhar
Antibodies, 2019
View PDFchevron_right
Monoclonal antibodies in the treatment of multiple myeloma
Beth Faiman
British Journal of Haematology, 2011
View PDFchevron_right
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
Jane Estell
Clinical hematology international, 2023
View PDFchevron_right
Targeted therapies in multiple myeloma
Andreas Charidimou
Targeted oncology, 2009
View PDFchevron_right
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab
Jhon Soto
Clinical Cancer Research, 2020
View PDFchevron_right
Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside
Luisa Giaccone, Marcello Rotta
Leukemia, 2005
View PDFchevron_right
Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24
Toshio Matsumoto
Blood, 1997
View PDFchevron_right
A phase 1 dose-escalation study of antibody BI-505 in relapsed/refractory multiple myeloma
Peter Gimsing
Clinical Cancer Research, 2015
View PDFchevron_right
Data from A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Titti Niskanen
View PDFchevron_right
Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
Bernard Buetow
Molecular Cancer Therapeutics, 2019
View PDFchevron_right
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Bart Barlogie
Clinical Cancer Research, 2008
View PDFchevron_right
Introductory Chapter: Multiple Myeloma in the Era of Novel Therapeutics
Khalid Al-Anazi
Update on Multiple Myeloma [Working Title]
View PDFchevron_right
The Role of Targeted Therapy in Multiple Myeloma
Silvia Ling
Resistance to Targeted Anti-Cancer Therapeutics, 2021
View PDFchevron_right
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Elisabetta Ada Cavalcanti-Adam
Cancer cell, 2017
View PDFchevron_right
Supplemental table 1 from A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Markus Hansson
View PDFchevron_right
Molecular Targets for the Treatment of Multiple Myeloma
Michele Caraglia
Current Cancer Drug Targets, 2012
View PDFchevron_right
Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies
Khalid Al-Anazi
IntechOpen eBooks, 2023
View PDFchevron_right
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
Luca Bertamini
Cancers, 2019
View PDFchevron_right
Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells
John Meekin
Leukemia, 2018
View PDFchevron_right
Recent Advances in the Treatment of Patients with Multiple Myeloma
Javier de la Rubia
Cancers
View PDFchevron_right
Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice
Roberto Castelli
Immunopharmacology and immunotoxicology, 2012
View PDFchevron_right
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
Weam Elbezanti
Pharmaceuticals
View PDFchevron_right
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
Ingemar Turesson
Leukemia, 2013
View PDFchevron_right
Development of target-specific treatments in multiple myeloma
Asher Chanan-khan, Ivan Borrello
British Journal of Haematology, 2010
View PDFchevron_right
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma
09 Hồ Bảo Khánh Huyền
Leukemia, 2020
View PDFchevron_right
Innovative Agents in Multiple Myeloma
Beth Faiman
Journal of the Advanced Practitioner in Oncology, 2014
View PDFchevron_right